Caffeine: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
mNo edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Caffeine''', contained in [[coffee]] and other drinks, is a mild stimulant and "is the most widely used psychoactive drug in the world."<ref name=" | '''Caffeine''', contained in [[coffee]] and other drinks, is a mild stimulant and "is the most widely used psychoactive drug in the world."<ref name="isbn9780071422802">{{cite book |author=O'Brien, Charles |authorlink= |editor=Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred |others= |title=Goodman & Gilman's The Pharmacological Basis of Therapeutics |edition=11th |chapter=Chapter 23. Drug Addiction and Drug Abuse |chapterurl= |language= |publisher=McGraw-Hill |location=New York |year=2006 |origyear= |pages= |quote= |isbn=9780071422802 |oclc= |doi= |url=http://www.accessmedicine.com/resourceTOC.aspx?resourceID=28 |accessdate=}}</ref> It is a member of the class of [[methylxanthine]]s, also containing [[theophylline]], [[theobromine]], and [[aminophylline]], which have similar but not identical actions (e.g., relatively more or less stimulation and bronchodilation). | ||
Cessation of caffeine intake can lead to withdrawal symptoms.<ref name="pmid1528206">{{cite journal |author=Silverman K, Evans SM, Strain EC, Griffiths RR |title=Withdrawal syndrome after the double-blind cessation of caffeine consumption |journal=The New England journal of medicine |volume=327 |issue=16 |pages=1109–14 |year=1992 |month=October |pmid=1528206 |doi= |url= |issn=}}</ref> | Cessation of caffeine intake can lead to withdrawal symptoms.<ref name="pmid1528206">{{cite journal |author=Silverman K, Evans SM, Strain EC, Griffiths RR |title=Withdrawal syndrome after the double-blind cessation of caffeine consumption |journal=The New England journal of medicine |volume=327 |issue=16 |pages=1109–14 |year=1992 |month=October |pmid=1528206 |doi= |url= |issn=}}</ref> | ||
==Pharmacology== | ==Pharmacology== | ||
Caffeine competitively antagonizes [[adenosine]] receptors. This antagonism prevents adenosine's inhibition of intracellular [[cyclic AMP]]. [[Cyclic AMP]] is a [[Second messenger system|second messenger]] that increases [[sympathetic nervous system|sympathetic]] stimulation and increases [[norepinephrine]] and [[dopamine]] release<ref name=" | Caffeine competitively antagonizes [[adenosine]] receptors. This antagonism prevents adenosine's inhibition of intracellular [[cyclic AMP]]. [[Cyclic AMP]] is a [[Second messenger system|second messenger]] that increases [[sympathetic nervous system|sympathetic]] stimulation and increases [[norepinephrine]] and [[dopamine]] release<ref name="isbn9780071422802" /> | ||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 17:00, 23 July 2024
Caffeine, contained in coffee and other drinks, is a mild stimulant and "is the most widely used psychoactive drug in the world."[1] It is a member of the class of methylxanthines, also containing theophylline, theobromine, and aminophylline, which have similar but not identical actions (e.g., relatively more or less stimulation and bronchodilation).
Cessation of caffeine intake can lead to withdrawal symptoms.[2]
Pharmacology
Caffeine competitively antagonizes adenosine receptors. This antagonism prevents adenosine's inhibition of intracellular cyclic AMP. Cyclic AMP is a second messenger that increases sympathetic stimulation and increases norepinephrine and dopamine release[1]
References
- ↑ 1.0 1.1 O'Brien, Charles (2006). “Chapter 23. Drug Addiction and Drug Abuse”, Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th. New York: McGraw-Hill. ISBN 9780071422802.
- ↑ Silverman K, Evans SM, Strain EC, Griffiths RR (October 1992). "Withdrawal syndrome after the double-blind cessation of caffeine consumption". The New England journal of medicine 327 (16): 1109–14. PMID 1528206. [e]